Sprycel — CareFirst (Caremark)

Initial criteria

• Treatment of widespread metastatic chondrosarcoma or recurrent chordoma
• Medication will be used as a single agent

Reauthorization criteria

• No evidence of unacceptable toxicity or disease progression while on current regimen

Approval duration

Initial and Reauthorization: 12 months